118 related articles for article (PubMed ID: 27494879)
1. Epigenetic activation of LY6K predicts the presence of metastasis and poor prognosis in breast carcinoma.
Kong HK; Park SJ; Kim YS; Kim KM; Lee HW; Kang HG; Woo YM; Park EY; Ko JY; Suzuki H; Chun KH; Song E; Jang KY; Park JH
Oncotarget; 2016 Aug; 7(34):55677-55689. PubMed ID: 27494879
[TBL] [Abstract][Full Text] [Related]
2. The regulatory mechanism of the LY6K gene expression in human breast cancer cells.
Kong HK; Yoon S; Park JH
J Biol Chem; 2012 Nov; 287(46):38889-900. PubMed ID: 22988241
[TBL] [Abstract][Full Text] [Related]
3. Ly6E/K Signaling to TGFβ Promotes Breast Cancer Progression, Immune Escape, and Drug Resistance.
AlHossiny M; Luo L; Frazier WR; Steiner N; Gusev Y; Kallakury B; Glasgow E; Creswell K; Madhavan S; Kumar R; Upadhyay G
Cancer Res; 2016 Jun; 76(11):3376-86. PubMed ID: 27197181
[TBL] [Abstract][Full Text] [Related]
4. miRNAs involved in LY6K and estrogen receptor α contribute to tamoxifen-susceptibility in breast cancer.
Kim YS; Park SJ; Lee YS; Kong HK; Park JH
Oncotarget; 2016 Jul; 7(27):42261-42273. PubMed ID: 27304060
[TBL] [Abstract][Full Text] [Related]
5. CpG island shore methylation regulates caveolin-1 expression in breast cancer.
Rao X; Evans J; Chae H; Pilrose J; Kim S; Yan P; Huang RL; Lai HC; Lin H; Liu Y; Miller D; Rhee JK; Huang YW; Gu F; Gray JW; Huang TM; Nephew KP
Oncogene; 2013 Sep; 32(38):4519-28. PubMed ID: 23128390
[TBL] [Abstract][Full Text] [Related]
6. LY6K promotes glioblastoma tumorigenicity via CAV-1-mediated ERK1/2 signaling enhancement.
Sastry NG; Wan X; Huang T; Alvarez AA; Pangeni RP; Song X; James CD; Horbinski CM; Brennan CW; Nakano I; Hu B; Cheng SY
Neuro Oncol; 2020 Sep; 22(9):1315-1326. PubMed ID: 32055849
[TBL] [Abstract][Full Text] [Related]
7. TGF-β induces global changes in DNA methylation during the epithelial-to-mesenchymal transition in ovarian cancer cells.
Cardenas H; Vieth E; Lee J; Segar M; Liu Y; Nephew KP; Matei D
Epigenetics; 2014 Nov; 9(11):1461-72. PubMed ID: 25470663
[TBL] [Abstract][Full Text] [Related]
8. Regulation of HK2 expression through alterations in CpG methylation of the HK2 promoter during progression of hepatocellular carcinoma.
Lee HG; Kim H; Son T; Jeong Y; Kim SU; Dong SM; Park YN; Lee JD; Lee JM; Park JH
Oncotarget; 2016 Jul; 7(27):41798-41810. PubMed ID: 27260001
[TBL] [Abstract][Full Text] [Related]
9. Serological antibodies against LY6K as a diagnostic biomarker in esophageal squamous cell carcinoma.
Zhang B; Zhang Z; Zhang X; Gao X; Kernstine KH; Zhong L
Biomarkers; 2012 Jun; 17(4):372-8. PubMed ID: 22515502
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic silencing of CREB3L1 by DNA methylation is associated with high-grade metastatic breast cancers with poor prognosis and is prevalent in triple negative breast cancers.
Ward AK; Mellor P; Smith SE; Kendall S; Just NA; Vizeacoumar FS; Sarker S; Phillips Z; Alvi R; Saxena A; Vizeacoumar FJ; Carlsen SA; Anderson DH
Breast Cancer Res; 2016 Jan; 18(1):12. PubMed ID: 26810754
[TBL] [Abstract][Full Text] [Related]
11. NT5E CpG island methylation is a favourable breast cancer biomarker.
Lo Nigro C; Monteverde M; Lee S; Lattanzio L; Vivenza D; Comino A; Syed N; McHugh A; Wang H; Proby C; Garrone O; Merlano M; Hatzimichael E; Briasoulis E; Gojis O; Palmieri C; Jordan L; Quinlan P; Thompson A; Crook T
Br J Cancer; 2012 Jun; 107(1):75-83. PubMed ID: 22653144
[TBL] [Abstract][Full Text] [Related]
12. LY6K is a novel molecular target in bladder cancer on basis of integrate genome-wide profiling.
Matsuda R; Enokida H; Chiyomaru T; Kikkawa N; Sugimoto T; Kawakami K; Tatarano S; Yoshino H; Toki K; Uchida Y; Kawahara K; Nishiyama K; Seki N; Nakagawa M
Br J Cancer; 2011 Jan; 104(2):376-86. PubMed ID: 21063397
[TBL] [Abstract][Full Text] [Related]
13. Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas.
Ishikawa N; Takano A; Yasui W; Inai K; Nishimura H; Ito H; Miyagi Y; Nakayama H; Fujita M; Hosokawa M; Tsuchiya E; Kohno N; Nakamura Y; Daigo Y
Cancer Res; 2007 Dec; 67(24):11601-11. PubMed ID: 18089789
[TBL] [Abstract][Full Text] [Related]
14. MMP9 gene expression regulation by intragenic epigenetic modifications in breast cancer.
Klassen LMB; Chequin A; Manica GCM; Biembengut IV; Toledo MB; Baura VA; de O Pedrosa F; Ramos EAS; Costa FF; de Souza EM; Klassen G
Gene; 2018 Feb; 642():461-466. PubMed ID: 29162512
[TBL] [Abstract][Full Text] [Related]
15. LY6K-AS lncRNA is a lung adenocarcinoma prognostic biomarker and regulator of mitotic progression.
Ali MM; Di Marco M; Mahale S; Jachimowicz D; Kosalai ST; Reischl S; Statello L; Mishra K; Darnfors C; Kanduri M; Kanduri C
Oncogene; 2021 Apr; 40(13):2463-2478. PubMed ID: 33674747
[TBL] [Abstract][Full Text] [Related]
16. TEX101, a glycoprotein essential for sperm fertility, is required for stable expression of Ly6k on testicular germ cells.
Endo S; Yoshitake H; Tsukamoto H; Matsuura H; Kato K; Sakuraba M; Takamori K; Fujiwara H; Takeda S; Araki Y
Sci Rep; 2016 Mar; 6():23616. PubMed ID: 27005865
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of leucine zipper putative tumor suppressor 1 is associated with poor prognosis, increased cell motility and invasion, and epithelial-to-mesenchymal transition characteristics in human breast carcinoma.
Wang XX; Zhu Z; Su D; Lei T; Wu X; Fan Y; Li X; Zhao J; Fu L; Dong JT; Fu L
Hum Pathol; 2011 Oct; 42(10):1410-9. PubMed ID: 21419475
[TBL] [Abstract][Full Text] [Related]
18. Negative/low HER2 expression alone or combined with E-cadherin positivity is predictive of better prognosis in patients with breast carcinoma.
Karray-Chouayekh S; Trifa F; Khabir A; Sellami-Boudawara T; Frikha M; Gargouri A; Mokdad-Gargouri R
Histol Histopathol; 2012 Mar; 27(3):377-85. PubMed ID: 22237715
[TBL] [Abstract][Full Text] [Related]
19. Lymphocyte antigen 6K signaling to aurora kinase promotes advancement of the cell cycle and the growth of cancer cells, which is inhibited by LY6K-NSC243928 interaction.
Selvanesan BC; Varghese S; Andrys-Olek J; Arriaza RH; Prakash R; Tiwari PB; Hupalo D; Gusev Y; Patel MN; Contente S; Sanda M; Uren A; Wilkerson MD; Dalgard CL; Shimizu LS; Chruszcz M; Borowski T; Upadhyay G
Cancer Lett; 2023 Apr; 558():216094. PubMed ID: 36805500
[TBL] [Abstract][Full Text] [Related]
20. LY6K depletion modulates TGF-β and EGF signaling.
Park S; Park D; Han S; Chung GE; Soh S; Ka HI; Joo HJ; Yang Y
Cancer Med; 2023 Jun; 12(11):12593-12607. PubMed ID: 37076981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
